Skip to main content

Table 6 The results of subgroup analyses

From: E-cadherin expression phenotypes associated with molecular subtypes in invasive non-lobular breast cancer: evidence from a retrospective study and meta-analysis

Variables No. of studies Pooled risk ratio (95% CI) I 2 statistic, % χ2 P value for heterogeneity Analytical model
Publication year
Before 2010 5 [12, 16, 22,23,24] 1.92 (1.30–2.83) 94 <0.001 REM
After 2011 7a [11, 17, 25,26,27,28] 1.58 (1.15–2.18) 89 <0.001 REM
Geographic location
Asia 7a [11, 16, 17, 24,25,26] 2.21 (1.66–2.94) 86 <0.001 REM
Europe 5 [12, 22, 23, 27, 28] 1.26 (1.06–1.51) 70 0.010 REM
Europe (exclude the lowest effect size [28]) 4 [12, 22, 23, 27] 1.29 (1.20–1.39) 22 0.280 FEM
Recruited period
Before 2000 4 [17b, 22, 23 b, 27] 1.29 (1.20–1.39) 10 0.340 FEM
2000 to 2006 4 [16, 24,25,26] 2.08 (1.40–3.08) 91 <0.001 REM
After 2006 2a [11] 2.77 (2.22–3.47) 0 0.700 FEM
Sample size (n, median)
≥452 6 [16, 17, 22, 23, 27, 28] 1.38 (1.07–1.78) 90 <0.001 REM
<452 6a [11, 12, 24,25,26] 2.35 (1.45–3.81) 90 <0.001 REM
≥1000 2 [22, 27] 1.27 (1.17–1.38) 0 0.420 FEM
Tissue processing
TMA 7 [11, 12, 17, 22, 23, 27, 28] 1.49 (1.13–1.95) 90 <0.001 REM
Whole slide section 5a [16, 24,25,26] 2.12 (1.49–3.04) 89 <0.001 REM
IHC antibodies
NCH-38 antibody 2 [11, 16] 2.49 (1.96–3.15) 64 0.090 REM
HECD-1 antibody 2 [12, 22] 1.50 (0.91–2.48) 71 0.060 REM
HECD-1 antibody 2 [12, 22] 1.27 (1.15–1.40) 71 0.060 FEM
4A2C7 antibody 3a [23, 24] 2.29 (1.00–5.25) 94 <0.001 REM
4A2C7 antibody (only whole slide section) 2a [24] 3.38 (2.47–4.62) 38 0.210 FEM
Cutoff
10% 3 [11, 25, 26] 1.85 (1.15–2.98) 92 <0.001 REM
30 and 50% 6a [12, 16, 23, 24, 28] 1.72 (1.02–2.90) 93 <0.001 REM
100 H-score 2 [22, 27] 1.27 (1.17–1.38) 0 0.420 FEM
Prevalence of E-cad expression (%, median)
>64% 6 a [11, 12, 17, 24, 28] 2.02 (1.22–3.36) 87 <0.001 REM
>64% (exclude the highest prevalence [28]) 5 a [11, 12, 17, 24] 2.74 (2.31–3.25) 40 0.150 FEM
≤64% 6 [16, 22, 23, 25,26,27] 1.47 (1.21–1.79) 88 <0.001 REM
≤50% 4 [22, 23, 26, 27] 1.27 (1.18–1.36) 0 0.880 FEM
NOS score
7 5 a [16, 22, 26, 27] 1.53 (1.20–1.96) 90 <0.001 REM
5 and 6 7 [11, 12, 17, 23,24,25, 28] 1.82 (1.21–2.72) 90 <0.001 REM
  1. CI confidence interval, REM random-effects model, FEM fixed-effects model
  2. aIncluding our retrospective study
  3. bMost half of recruited period before 2000